The NOAEL Equivalent of Environmental Cadmium Exposure Associated with GFR Reduction and Chronic Kidney Disease

Soisungwan Satarug, Aleksandra Buha Đorđević, Supabhorn Yimthiang, David A. Vesey and Glenda C. Gobe

Abstract: Cadmium (Cd) is a highly toxic metal pollutant present in virtually all food types. Health guidance values were established to safeguard against excessive dietary Cd exposure. The derivation of such health guidance figures has been shifted from the no-observed-adverse-effect level (NOAEL) to the lower 95% confidence bound of the benchmark dose (BMD), termed BMDL. Here, we used the PROAST software to calculate the BMDL figures for Cd excretion (E\textsubscript{Cd}) associated with a reduction in the estimated glomerular filtration rate (eGFR), and an increased prevalence of chronic kidney disease (CKD), defined as eGFR ≤ 60 mL/min/1.73 m\textsuperscript{2}. Data were from 1189 Thai subjects (493 males and 696 females) mean age of 43.2 years. The overall percentages of smokers, hypertension and CKD were 33.6%, 29.4% and 6.2%, respectively. The overall mean E\textsubscript{Cd} normalized to the excretion of creatinine (E\textsubscript{cr}) as E\textsubscript{Cd}/E\textsubscript{cr} was 0.64 µg/g creatinine. E\textsubscript{Cd}/E\textsubscript{cr}, age and body mass index (BMI) were independently associated with increased prevalence odds ratios (POR) for CKD. BMI figures ≥ 24 kg/m\textsuperscript{2} were associated with an increase in POR for CKD by 2.81-fold (p = 0.028). E\textsubscript{Cd}/E\textsubscript{cr} values of 0.38–2.49 µg/g creatinine were associated with an increase in POR for CKD risk by 6.2-fold (p = 0.001). The NOAEL equivalent figures of E\textsubscript{Cd}/E\textsubscript{cr} based on eGFR reduction in males, females and all subjects were 0.839, 0.849 and 0.828 µg/g creatinine, respectively. The BMDL/BMDU values of E\textsubscript{Cd}/E\textsubscript{cr} associated with a 10% increase in CKD prevalence were 2.77/5.06 µg/g creatinine. These data indicate that Cd-induced eGFR reduction occurs at relatively low body burdens and that the population health risk associated with E\textsubscript{Cd}/E\textsubscript{cr} of 2.77–5.06 µg/g creatinine was not negligible.

Keywords: benchmark dose; BMDL; BMDU; cadmium; creatinine clearance; chronic kidney disease; eGFR; NOAEL; urine cadmium

1. Introduction

Environmental exposure to cadmium (Cd) is inevitable for most people because the metal is present in almost all food types [1–3]. The realization in the 1940s that the condition referred to as “itai-itai” disease was due to the consumption of rice heavily contaminated with Cd brought into focus the real threat to health posed by this metal [4,5]. Itai-itai disease is the most severe form of human Cd poisoning, characterized by severe damage to the kidneys and bones, resulting in multiple bone fractures due to osteoporosis and osteomalacia [4,5]. The pathologic symptoms of the itai-itai disease have been replicated in Cd-treated cynomolgus monkeys [6].
To safeguard against excessive dietary Cd exposure, health guidance such as a tolerable intake level of Cd was established [7]. The Joint FAO/WHO Expert Committee on Food Additives and Contaminants (JECFA) considered the kidney to be the critical target of Cd toxicity [8]. By definition, the provisional tolerable weekly intake (PTWI) for a chemical with no known biological function is an estimate of the amount that can be ingested weekly over a lifetime without appreciable health risk. Subsequently, the PTWI for Cd was amended to a tolerable monthly intake (TMI) of 25 µg per kg body weight per month, equivalent to 0.83 µg per kg body weight per day [8]. This tolerable intake level for Cd was derived from a risk assessment model that assumed an increase in excretion of β2-microglobulin (β2M) (Eβ2M) above 300 µg/g creatinine as the point of departure (POD) [8]. However, we have shown that such an increase in Eβ2M reflected tubular dysfunction and nephron loss, evident from a reduction in estimated glomerular filtration rate (eGFR) to 60 mL/min/1.73 m² or below [9,10]. In effect, a tolerable intake level of Cd derived from the Eβ2M-based POD is not sufficiently low to be without an impact on human health.

Current evidence suggests that sufficient tubular injury disables glomerular filtration and leads to nephron atrophy and a decrease in GFR [11–13]. Accordingly, we argue that a reduction in eGFR due to Cd nephropathy could serve as the POD from which health guidance values should be derived. Owing to some shortcomings of the no-observed-adverse-effect level (NOAEL), the benchmark dose (BMD) has been used as the POD [7,14–16]. The BMD is a dose level, derived from an estimated dose–response curve, associated with a specified change in response, termed benchmark response (BMR) which can be set at 1%, 5%, or 10% as required [14–16].

The present study had two major aims. The first aim was to characterize a reduction in eGFR and risk factors of chronic kidney disease (CKD) in a sufficiently large group of people with a wide range of environmental Cd exposure. The risk factors considered included age, body mass index (BMI), smoking, hypertension, and Cd exposure measured as excretion of Cd (ECd). The second aim was to compute the lower 95% confidence bound of BMD (BMDL) and the BMD upper confidence limit (BMDU) of ECd associated with eGFR reduction and an increase in the prevalence of CKD.

2. Materials and Methods

2.1. Participants

To represent a large group of subjects with a wide range of environmental Cd exposure levels suitable for the dose–response analysis and health risk calculation, we assembled archived data from 1189 persons who participated in large population-based studies undertaken in a Cd contamination area in the Mae Sot District, Tak Province (n = 537), and low exposure locations in Bangkok and Nakhon–Si–Thammarat Province (n = 652). The Institutional Ethical Committees of Chulalongkorn University, Chiang Mai University and the Mae Sot Hospital approved the study protocol for the Mae Sot and Bangkok groups. The Office of the Human Research Ethics Committee of Walailak University in Thailand approved the study protocol for the Nakhon Si Thammarat group [17,18].

All participants gave informed consent prior to participation. They had lived at their current addresses for at least 30 years. Exclusion criteria were pregnancy, breastfeeding, a history of metalwork, and a hospital record or physician’s diagnosis of advanced chronic disease. Because occupational exposure was an exclusion criterion, we presumed that all participants had acquired Cd from the environment. Diabetes was defined as fasting plasma glucose levels ≥ 126 mg/dL or a physician’s prescription of anti-diabetic medications. Hypertension was defined as systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, a physician’s diagnosis, or prescription of anti-hypertensive medications.

2.2. Collection and Analysis of Biological Specimens

Simultaneous blood and urine sampling are required to normalize ECd to Ccr. Accordingly, second-morning urine samples were collected after an overnight fast, and whole blood samples were obtained within 3 hours after the urine sampling. Aliquots of urine,
whole blood and plasma were stored at $-20 \, ^\circ C$ or $-80 \, ^\circ C$ for later analysis. The assay for urine and plasma concentrations of creatinine ($[cr]_u$ and $[cr]_p$) was based on the Jaffe reaction.

For the Bangkok group, urine concentration of Cd ($[Cd]_u$) was determined by inductively-coupled plasma mass spectrometry (ICP/MS, Agilent 7500, Agilent Technologies, Santa Clara, CA, USA). Multi-element standards (EM Science, EM Industries, Inc., Newark, NJ, USA) were used to calibrate the Cd analyses. Quality assurance and control were conducted with simultaneous analyses of the reference urine Lyphocheck® (Bio-Rad, Gladesville, New South Wales, Australia), which contained low- and high-range Cd levels. A coefficient of variation value of 2.5% was obtained for Cd in the reference urine. The low limit of detection (LOD) of urine Cd was 0.05 µg/L. The urine samples containing Cd below the LOD were assigned as the LOD divided by the square root of 2 [19].

For the Nakhon–Si–Thammarat group, $[Cd]_u$ was determined with the GBC System 5000 Graphite Furnace Atomic Absorption Spectrophotometer (AAS) (GBC Scientific Equipment, Hampshire, IL, USA). Instrumental metal analysis was calibrated with multi-element standards (Merck KGaA, Darmstadt, Germany). Reference urine metal control levels 1, 2, and 3 (Lyphocheck, Bio-Rad, Hercules, CA, USA) were used for quality control, analytical accuracy, and precision assurance. The analytical accuracy of metal detection was checked by an external quality assessment every 3 years. The LOD of urine Cd was 0.1 µg/L. When $[Cd]_u$ was below its detection limit, the Cd concentration assigned was the detection limit divided by the square root of 2 [19].

For the Mae Sot group, $[Cd]_u$ was determined with AAS (Shimadzu Model AA-6300, Kyoto, Japan). Urine standard reference material No. 2670 (National Institute of Standards, Washington, DC, USA) was used for quality assurance and control purposes. The LOD of Cd quantitation, defined as 3 times the standard deviation of blank measurements was 0.06 µg/L. None of the urine samples from this group contained $[Cd]_u$ below the detection limit.

2.3. Estimated Glomerular Filtration Rates (eGFR)

The GFR is the product of nephron number and mean single nephron GFR, and in theory, the GFR is indicative of nephron function [20–22]. In practice, the GFR is estimated from established chronic kidney disease-epidemiology collaboration (CKD-EPI) equations and is reported as eGFR [21].

Male eGFR = 141 × \[\frac{\text{plasma creatinine}}{0.9}\]^Y × 0.993^age, where Y = −0.411 if $[cr]_p \leq 0.9 \, \text{mg/dL}$, Y = −1.209 if $[cr]_p > 0.9 \, \text{mg/dL}$. Female eGFR = 144 × \[\frac{\text{plasma creatinine}}{0.7}\]^Y × 0.993^age, where Y = −0.329 if $[cr]_p \leq 0.7 \, \text{mg/dL}$, Y = −1.209 if $[cr]_p > 0.7 \, \text{mg/dL}$. For dichotomous comparisons, CKD was defined as eGFR ≤ 60 mL/min/1.73 m^2. CKD stages 1, 2, 3a, 3b, 4, and 5 corresponded to eGFR of 90–119, 60–89, 45–59, 30–44, 15–29, and <15 mL/min/1.73 m^2, respectively.

2.4. Normalization of $E_{Cd}$ to $E_{cr}$ and $C_{cr}$

$E_x$ was normalized to $E_{cr}$ as $[x]_u/[cr]_u$, where x = Cd; $[x]_u$ = urine concentration of x (mass/volume); and $[cr]_u$ = urine creatinine concentration (mg/dL). The ratio $[x]_u/[cr]_u$ was expressed in µg/g of creatinine.

$E_x$ was normalized to $C_{cr}$ as $E_x/C_{cr} = [x]_u [cr]_p/[cr]_u$, where x = Cd; $[x]_u$ = urine concentration of x (mass/volume); $[cr]_p$ = plasma creatinine concentration (mg/dL); and $[cr]_u$ = urine creatinine concentration (mg/dL). $E_x/C_{cr}$ was expressed as the excretion of x per volume of filtrate [23].

2.5. Benchmark Dose Computation and Benchmark Dose–Response (BMR) Setting

We used the web-based PROAST software version 70.1 (https://proastweb.rivm.nl accessed on 13 October 2022) to compute the BMD figures for $E_{Cd}/E_{cr}$ and $E_{Cd}/C_{cr}$ associated with glomerular dysfunction. A specific effect size termed the benchmark response (BMR) was set at 5% for a continuous eGFR reduction endpoint and at 10%
for a quantal endpoint where $eGFR \leq 60 \text{ mL/min}/1.73 \text{ m}^2$. For a continuous endpoint, BMD values were computed from fitting datasets to four dose–response models, including inverse exponential, natural logarithmic, exponential, and Hill models. For a quantal endpoint, BMD values were calculated from fitting datasets to seven dose–response models that included two-stage, logarithmic logistic, Weibull, logarithmic probability, gamma, exponential and Hill models. The BMD 95% confidence intervals of $E_{Cd}/E_{cr}$ and $E_{Cd}/C_{cr}$ were from model averaging using bootstrap with 200 repeats.

The BMDL and BMDU corresponded to the lower bound and upper bound of the 95% confidence interval (CI) of BMD. The wider the BMDL-BMDU difference, the higher the statistical uncertainty in the dataset [23–26]. BMDL/BMDU figures of $E_{Cd}$ for the glomerular endpoint were calculated for males, females and all subjects.

2.6. Statistical Analysis

Data were analyzed with IBM SPSS Statistics 21 (IBM Inc., New York, NY, USA). The one-sample Kolmogorov–Smirnov test was used to identify departures of continuous variables from a normal distribution, and a logarithmic transformation was applied to variables that showed rightward skewing before they were subjected to parametric statistical analysis. The Mann–Whitney U-test was used to compare mean differences between the two groups. The Chi-square test was used to determine differences in percentage and prevalence data. The multivariable logistic regression analysis was used to determine the Prevalence Odds Ratio (POR) for CKD in relation to six independent variables; age, BMI, gender, smoking, hypertension and Cd exposure measures as $E_{Cd}$. We employed two models in each logistic regression analysis: model 1 incorporated $\log_2(E_{Cd}/E_{cr})$ or three $E_{Cd}/E_{cr}$ groups; model 2 incorporated $\log_2(E_{Cd}/C_{cr})$ or three $E_{Cd}/C_{cr}$ groups. All other independent variables in models 1 and 2 were identical. For all tests, $p$-values $\leq 0.05$ for two-tailed tests were assumed to indicate statistical significance.

3. Results

3.1. Characterization of Cadmium Exposure by Sex and Smoking

Table 1 provides demographic data of participants (493 males and 696 females) stratified by sex and smoking status.

The overall mean age of participants was 43.2 years, and the overall percentages of current smokers plus those who had stopped smoking for less than 10 years, hypertension and low eGFR were 33.6%, 29.4% and 6.2%, respectively. The overall mean $[\text{Cd}]_u$ and mean $E_{Cd}/E_{cr}$ were 0.94 $\mu g/L$ and 0.64 $\mu g/g$ creatinine, while the overall mean $E_{Cd}/C_{cr} \times 100$ was 1.02 $\mu g/L$ filtrate.

Smoking was higher among males (57.4%) than females (16.4%). In both sexes, % of smokers and non-smokers with hypertension did not differ. However, % of low eGFR among smokers was 3.7- and 3.8-fold higher than non-smokers in female and male groups, respectively. For the female group only, the mean BMI was 6 % lower in smokers than non-smokers ($p = 0.004$).

For the male group, the mean $[\text{Cd}]_u$ in smokers was 5.4-fold higher than nonsmokers (1.73 vs. 0.32 $\mu g/L$, $p < 0.001$). Mean $E_{Cd}/E_{cr}$ and mean $E_{Cd}/C_{cr}$ in smokers were 2.9- and 4.1-fold higher than in nonsmokers, respectively.

For the female group, the mean $[\text{Cd}]_u$ in smokers was 6.4-fold higher than nonsmokers (4.84 vs. 0.75 $\mu g/L$, $p < 0.001$). Mean $E_{Cd}/E_{cr}$ and mean $E_{Cd}/C_{cr}$ in smokers were 3.2- and 6-fold higher than in nonsmokers, respectively.
Table 1. Characteristics of participants stratified by sex and smoking status.

| Parameters                              | All subjects n 1189 (33.6% Smokers) | Males, n 493 (57.4% Smokers) | Females, n 696 (16.8% Smokers) |
|-----------------------------------------|-------------------------------------|-----------------------------|----------------------------------|
|                                         |                                     | Nonsmokers n 210            | Smokers n 283                     | Nonsmokers n 579               | Smokers n 117 |
| Age, years                              | 43.2 ± 14.0                         | 35.9 ± 13.0                 | 45.0 ± 14.8 ***                  | 42.6 ± 12.9                    | 54.2 ± 10.1 ### |
| Hypertension (%)                        | 29.4                                | 26.5                        | 27.2                             | 30.8                            | 33.3          |
| BMI, kg/m²                               | 23.0 ± 3.9                          | 22.4 ± 3.0                  | 22.3 ± 3.4                       | 23.8 ± 4.0                      | 22.4 ± 4.6  |
| BMI groups (%)                           |                                     |                              |                                  |                                 |               |
| 12–18                                   | 10.5                                | 9.2                         | 12.2 *                           | 7.4                             | 21.4          |
| 19–23                                   | 47.1                                | 56.9                        | 57.2 **                          | 41.6                            | 36.8 ###      |
| ≥24                                     | 42.4                                | 34.0                        | 30.6                             | 51.0                            | 41.9 ###      |
| eGFR, mL/min/1.73 m²                    |                                     | 93.7 ± 20                   | 96.6 ± 17.6                      | 91.9 ± 22.1                     | 95.9 ± 19.3   | 81.8 ± 22.0 ### |
| eGFR ≤ 60                               |                                     | 6.2                         | 2.4                              | 8.8 **                          | 4.3           | 16.2 ###      |
| eGFR, mL/min/1.73 m² (%)                |                                     |                              |                                  |                                 |               |
| >120                                    | 7.8                                 | 9.0                         | 5.7                              | 9.7                             | 1.7 ###       |
| 90–120                                  | 53.8                                | 61.0                        | 56.5                             | 54.1                            | 33.3 ###      |
| 60–89                                   | 32.8                                | 27.6                        | 29.7 *                           | 32.8                            | 49.6 ###      |
| 30–59                                   | 5.0                                 | 1.9                         | 7.1 **                           | 3.3                             | 13.7          |
| 15–29                                   | 0.6                                 | 0.5                         | 1.1                              | 0.2                             | 1.7          |
| Plasma creatinine, mg/dL                | 0.88 ± 0.24                         | 1.00 ± 0.21                 | 1.00 ± 0.27                      | 0.76 ± 0.16                     | 0.82 ± 0.27 ** |
| Urine creatinine, mg/dL                 | 104.4 ± 73.5                        | 81.1 ± 78                   | 107.0 ± 75.6 ***                 | 67.9 ± 68.9                     | 79.8 ± 64.8  |
| Normalized to Ecr as Ecd/Ecr c           | 0.94 ± 9.69                         | 0.32 ± 5.96                 | 1.73 ± 15.9 ***                  | 0.75 ± 6.46                     | 4.84 ± 6.38 *** |
| Ecd/Ecr µg/g creatinine                 | 0.64 ± 6.12                         | 0.32 ± 3.29                 | 0.94 ± 8.85 ***                  | 0.57 ± 4.62                     | 1.83 ± 7.27 ### |
| Normalized to Ccr as Ecd/Ccr d           |                                     |                              |                                  |                                 |               |
| Ecd/Ccr × 100, µg/L filtrate            | 1.02 ± 8.19                         | 0.39 ± 4.75                 | 1.61 ± 12.61 ***                 | 0.83 ± 5.27                     | 5.00 ± 9.36 ### |

n, number of subjects; BMI, body mass index; eGFR, estimated glomerular filtration rate; Ecr, creatinine; Ccr, clearance of creatinine. a eGFR determined with Chronic Kidney Disease Epidemiology Collaboration (CKD–EPI) equations [20]; b eGFR of 90–119, 60–89, 45–59, 30–44, 15–29, and <15 mL/min/1.73 m² corresponded to CKD stages 1, 2, 3a, 3b, 4, and 5, respectively. c Ecr/Ecd = [x]cr/[x]cd; d Ecd/Ccr = [x]cd/[x]cr. e Where x = Cd [23]. Data for age, eGFR and BMI are arithmetic means ± standard deviation (SD). Data for all other continuous variables are geometric means ± SD. Data for BMI are from 951 subjects; data for hypertension are from 917 subjects; data for all other variables are from 1189 subjects. For each test, p ≤ 0.05 identifies statistical significance, determined by Chi-Square test and Mann–Whitney U test for % differences and mean differences, respectively. Compared with non-smoking males * p = 0.029–0.042, ** p = 0.001–0.006, *** p ≤ 0.001. Compared with non-smoking females, # p = 0.004, ## p = 0.001, ### p ≤ 0.001.

3.2. Characterization of CKD Risk factors

Table 2 provides the results of a logistic regression analysis where Ecd/Ecr and Ecd/Ccr were continuous variables, while age and BMI were categorical variables.

An independent effect on the POR for CKD was observed for Ecd/Ecr, BMI and age (Table 2). Sex, smoking and hypertension were not associated with the POR for CKD. Doubling of Ecd/Ecr was associated with an increase in POR for CKD by 1.47-fold (p < 0.001). BMI figures ≥ 24 kg/m² were associated with 2.81-fold increase in POR for CKD (p = 0.028). Compared with those aged 16–45 years, the POR values for CKD were 14-, 28- and 141-fold higher in those aged 46–55, 56–65, and 66–87 years, respectively.

In an equivalent analysis of the Ccr-normalized datasets, Ecd/Ccr, BMI and age were independently associated with increased POR for CKD. Sex, smoking and hypertension

Toxins 2022, 10, 614
5 of 16
were not associated with the POR for CKD. Doubling of \( \frac{E_{Cd}}{C_{cr}} \) was associated with an increase in POR for CKD by 1.96-fold \((p < 0.001)\). BMI figures \( \geq 24 \text{ kg/m}^2 \) were associated with a 3.12-fold increase in POR for CKD \((p = 0.022)\). Compared with those aged 16–45 years, the POR values for CKD were 10-, 35- and 199-fold higher in those aged 46–55, 56–65, and 66–87 years, respectively.

Table 2. Increment in risk of chronic kidney disease in relation to age, BMI and cadmium exposure.

| Independent Variables/Factors | Number of Subjects | \( \beta \) Coefficients POR 95% CI \( p \) |
|------------------------------|-------------------|----------------|-----------------|-----------------|-----------------|
| \( \log_2 \left[ \frac{E_{Cd}}{E_{cr}} \times 10^3 \right], \mu g/g creatinine \) | 917 | 0.385 (0.072) | 1.470 | 1.276 | 1.692 | \(<0.001\) |
| Hypertension | 276 | 0.490 (0.312) | 1.632 | 0.885 | 3.008 | 0.117 |
| Gender (female) | 562 | 0.028 (0.340) | 1.029 | 0.528 | 2.002 | 0.934 |
| Smoking | 335 | 0.209 (0.337) | 1.232 | 0.637 | 2.383 | 0.536 |
| BMI, kg/m\(^2\) | | | | | | |
| 12–18 | 99 | Referent | | | | |
| 19–23 | 431 | 0.057 (0.426) | 1.058 | 0.459 | 2.439 | 0.894 |
| \( \geq 24 \) | 387 | 1.033 (0.470) | 2.810 | 1.118 | 7.064 | 0.028 |
| Age, years | | | | | | |
| 16–45 | 392 | Referent | | | | |
| 46–55 | 348 | 2.655 (1.036) | 14.23 | 1.867 | 108.4 | 0.010 |
| 56–65 | 100 | 3.340 (1.059) | 28.21 | 3.538 | 224.9 | 0.002 |
| 66–87 | 77 | 4.950 (1.055) | 141.2 | 17.87 | 1116 | <0.001 |

Model 2

| Independent Variables/Factors | Number of Subjects | \( \beta \) Coefficients POR 95% CI \( p \) |
|------------------------------|-------------------|----------------|-----------------|-----------------|-----------------|
| \( \log_2 \left[ \frac{E_{Cd}}{C_{cr}} \times 10^5 \right], \mu g/L filtrate \) | 917 | 0.674 (0.107) | 1.962 | 1.589 | 2.422 | \(<0.001\) |
| Hypertension | 276 | 0.551 (0.326) | 1.735 | 0.916 | 3.287 | 0.091 |
| Gender (female) | 562 | −0.174 (0.366) | 0.840 | 0.410 | 1.719 | 0.633 |
| Smoking | 335 | −0.058 (0.351) | 0.944 | 0.474 | 1.879 | 0.869 |
| BMI, kg/m\(^2\) | | | | | | |
| 12–18 | 99 | Referent | | | | |
| 19–23 | 431 | 0.103 (0.457) | 1.109 | 0.452 | 2.717 | 0.822 |
| \( \geq 24 \) | 387 | 1.147 (0.500) | 3.150 | 1.181 | 8.400 | 0.022 |
| Age, years | | | | | | |
| 16–45 | 392 | Referent | | | | |
| 46–55 | 348 | 2.298 (1.036) | 9.951 | 1.305 | 75.88 | 0.027 |
| 56–65 | 100 | 3.543 (1.062) | 34.57 | 4.312 | 277.2 | 0.001 |
| 66–87 | 77 | 5.292 (1.066) | 198.6 | 24.59 | 1605 | <0.001 |

POR, Prevalence Odds Ratio; S.E., standard error of mean; CI, confidence interval. \( ^a \) CKD was defined as estimated glomerular filtration rate (eGFR) \( \leq 60 \text{ mL/min/1.73 m}^2 \). Coding: female = 1, male = 2, hypertensive = 1, normotensive = 2, smoker = 1, non-smoker = 2. Data were generated from logistic regression analyses relating POR for CKD to six independent variables, listed in the first column. For all tests, \( p \)-values < 0.05 indicate statistical significance. \( \log_2 \left[ \frac{E_{Cd}}{E_{cr}} \times 10^3 \right] \) was incorporated into model 1; \( \log_2 \left[ \frac{E_{Cd}}{C_{cr}} \times 10^5 \right] \) was incorporated into model 2. Other independent variables in models 1 and 2 were identical. \( \beta \) coefficients indicate an effect size of each independent variable on POR for CKD.

3.3. Cadmium Excretion in Relation to the Risk of CKD

Table 3 provides the results of a logistic regression analysis where age and BMI were continuous variables, while \( E_{Cd}/E_{cr} \) was a categorical variable in model 1, and \( E_{Cd}/C_{cr} \) was categorical in model 2.
Table 3. Dose–response relationship between cadmium excretion and the risk of chronic kidney disease.

| Independent Variables/ Factors | Number of Subjects | β Coefficients (SE) | POR (95% CI) | \( p \) |
|--------------------------------|--------------------|---------------------|--------------|------|
|                                |                    | \( \beta \)         | Lower        | Upper |      |
| **Model 1**                    |                    | \( \beta \)         | Lower        | Upper |      |
| Age, years                     | 917                | 0.126 (0.016)       | 1.135        | 1.100 | 1.170 | <0.001|
| BMI, kg/m²                     | 917                | 0.082 (0.038)       | 1.109        | 1.086 | 1.169 | 0.028 |
| Gender (female)                | 562                | 0.124 (0.337)       | 1.132        | 0.585 | 2.190 | 0.713 |
| Hypertension                   | 276                | 0.304 (0.310)       | 1.355        | 0.738 | 2.486 | 0.327 |
| Smoking                        | 335                | 0.173 (0.345)       | 1.189        | 0.605 | 2.338 | 0.615 |
| \( E_{Cd}/E_{Cr} \), µg/g creatinine |                  |                    |              |      |      |      |
| \( \leq 0.37 \)                | 358                | Referent            |              |      |      |      |
| 0.38–2.49                      | 333                | 1.819 (0.565)       | 6.164        | 2.035 | 18.67 | 0.001 |
| \( \geq 2.5 \)                 | 226                | 2.362 (0.557)       | 10.61        | 3.562 | 31.60 | <0.001|
| **Model 2**                    |                    | \( \beta \)         | Lower        | Upper |      |
| Age, years                     | 917                | 0.141 (0.016)       | 1.152        | 1.116 | 1.189 | <0.001|
| BMI, kg/m²                     | 917                | 0.099 (0.039)       | 1.104        | 1.023 | 1.191 | 0.011 |
| Gender (female)                | 562                | 0.191 (0.356)       | 1.211        | .602  | 2.434 | 0.591 |
| Hypertension                   | 276                | 0.240 (0.314)       | 1.271        | 0.687 | 2.353 | 0.445 |
| Smoking                        | 335                | −0.033 (0.359)      | 0.968        | 0.479 | 1.956 | 0.927 |
| \( E_{Cd}/C_{Cr} \), ng/L filtrate |                  |                    |              |      |      |      |
| \( \leq 9.9 \)                 | 346                | Referent            |              |      |      |      |
| 10–49.9                        | 326                | 1.470 (0.642)       | 4.350        | 1.237 | 15.30 | 0.022 |
| \( \geq 50 \)                  | 245                | 3.036 (0.637)       | 20.82        | 5.979 | 72.52 | <0.001|

POR, Prevalence Odds Ratio; S.E., standard error of mean; CI, confidence interval. \( ^a \) CKD was defined as estimated glomerular filtration rate (eGFR) \( \leq 60 \) mL/min/1.73 m². Coding: female = 1, male = 2, hypertensive = 1, normotensive = 2, smoker = 1, non-smoker = 2. Data were generated from logistic regression analyses relating POR for CKD to six independent variables listed in the first column. For all tests, \( p \)-values < 0.05 indicate statistical significance. Three \( E_{Cd}/E_{Cr} \) categories were incorporated into model 1; three \( E_{Cd}/C_{Cr} \times 100 \) categories were incorporated into model 2. Other independent variables in models 1 and 2 were identical. \( \beta \) coefficients indicate an effect size of each independent variable on POR for CKD.

Age and BMI were independently associated with increased POR for CKD in both models 1 and 2. Compared with \( E_{Cd}/E_{Cr} \leq 0.37 \) µg/g creatinine (model 1), the POR for CKD was increased by 6.2- and 10.6-fold in those with \( E_{Cd}/E_{Cr} \) values of 0.38–2.49 and \( \geq 2.5 \) µg/g creatinine, respectively. Compared with \( E_{Cd}/C_{Cr} \leq 9.9 \) ng/L filtrates (model 2), the POR for CKD was increased by 4.4- and 20.8-fold in those with \( E_{Cd}/C_{Cr} \) values of 10–49.9 and \( \geq 50 \) ng/L filtrate, respectively.

3.4. BMDL/BMDU Figures of \( E_{Cd} \) Associated with Reduced Glomerular Function
3.4.1. \( E_{Cr} \)-Normalized Dataset

As data in Figures 1 and 2 indicate, the differences between BMDL and BMDU figures of \( E_{Cd}/E_{Cr} \) were small for both continuous and quantal endpoints. The BMDL-BMDU figures of \( E_{Cd}/E_{Cr} \) calculated from Cd-dose and eGFR response models were higher in females than males.
Figure 1. BMD estimates of $E_{Cd}/E_{cr}$ from eGFR reduction endpoint with BMR at 5%. $E_{Cd}/E_{cr}$ and eGFR data were fitted to an inverse exponential model (a), a natural logarithmic model (b), an exponential model (c), and Hill model (d). Bootstrap curves were based on model averaging of $E_{Cd}/E_{cr}$ BMD estimates for all subjects (e). Outputs of all fitted models as BMDL and BMDU estimates of $E_{Cd}/E_{cr}$ associated with a 5% reduction in eGFR (f).

| 5% eGFR reduction | 95% CI of BMD $^a$ | U/L ratio |
|--------------------|--------------------|-----------|
| Men                | 0.839 1.81 2.157   | 2.157     |
| Women              | 0.849 1.74 2.049   | 2.049     |
| All                | 0.828 1.71 2.065   | 2.065     |

$^a$ BMD value of $E_{Cd}/E_{cr}$ was as µg/g creatinine. CI, confidence interval; U/L, BMDU/BMDL.
3.4.2. Ccr-Normalized Dataset

As data in Figures 3 and 4 indicate, the differences between BMDL and BMDU figures of $E_{Cd}/C_{cr}$ were small for both continuous and quantal endpoints. The BMDL-BMDU figures of $E_{Cd}/E_{cr}$ calculated by Cd-dose and eGFR response models in males and females were nearly identical.

For all subjects, the BMDL/BMDU of $E_{Cd}/C_{cr}$ for continuous and quantal endpoints were 10.4/24 and 56.1/83.1 ng/L filtrate, respectively.
Figure 3. BMD estimates of $E_{Cd}/C_{cr}$ from eGFR reduction endpoint with BMR at 5%. $E_{Cd}/C_{cr}$ and eGFR data were fitted to an inverse exponential model (a), a natural logarithmic model (b), an exponential model (c), and Hill model (d). Bootstrap curves were based on model averaging of $E_{Cd}/C_{cr}$ BMD estimates for all subjects (e). Outputs of all fitted models as BMDL and BMDU estimates of $E_{Cd}/C_{cr}$ associated with a 5% reduction in eGFR (f).

| 5% eGFR reduction | 95% CI of BMD $^a$ | U/L ratio |
|--------------------|--------------------|-----------|
|                    | Lower      | Upper     |           |
| Men                | 11.3       | 24.3      | 2.150     |
| Women              | 11.3       | 24.1      | 2.133     |
| All                | 10.4       | 24        | 2.308     |

$^a$ BMD value of $E_{cd}/C_{cr}$ in ng/L filtrate. CI, confidence interval; U/L, BMDU/BMDL.
With CKD has been observed in population-based studies in the U.S. [31–34], Taiwan [35], and Korea [36–38]. In a dose–response analysis of a large dataset from apparently healthy participants (mean age 48.3 years), older age and higher BMI were independently associated with higher risks of CKD, based on the low eGFR criterion (Table 2). These findings are consistent with the literature reports of age, overweight and obesity as common CKD risk factors [27–30]. In addition to these two risk factors, we have found the measure of long-term exposure to Cd (E_{Cd}/E_{cr}) to be another independent risk factor of CKD (Table 3). An association between low environmental Cd exposure and a decrease in eGFR to levels commensurate with CKD has been observed in population-based studies in the U.S. [31–34], Taiwan [35] and Korea [36–38].

In this study, the risk of CKD was increased by 6.2- and 10.6-fold, when E_{Cd}/E_{cr} ≤ 0.37 µg/g creatinine rose to 0.38–2.49 and ≥ 2.5 µg/g creatinine, respectively. These Cd-dose dependent increases in the risk of CKD were strengthened by the results obtained from the C_{cr}-normalized dataset where the risk of CKD was increased by 4.4- and 20.8-fold, comparing E_{Cd}/C_{cr} ≤ 9.9 ng/L filtrates with E_{Cd}/C_{cr} of 10–49.9 and ≥50 ng/L filtrate, respectively. This confirmation is noteworthy because normalizing E_{Cd} to E_{cr} can cause a wide dispersion of dataset due to the interindividual differences in E_{cr} such as muscle mass which is unrelated to neither Cd exposure nor nephron function [11,12].

Because of such increased variance in datasets introduced by E_{cr}-normalization, the effect of chronic exposure to low-dose Cd on eGFR was not realized. For example, a systematic review and meta-analysis of pooled data from 28 studies reported that the risk of proteinuria was increased by 1.35-fold when comparing the highest vs. lowest category of Cd dose metrics, but an increase in the risk of low eGFR was statistically insignificant (p = 0.10) [39]. An erroneous conclusion that chronic Cd exposure was not associated with a progressive eGFR reduction was also made in another systematic review [40].

**Figure 4.** BMD estimates of E_{Cd}/E_{cr} from quantal eGFR endpoint with BMR at 10%. Bootstrap curves were based on model averaging 95% confidence intervals of BMD of E_{Cd}/E_{cr} in males and females (a) and in all subjects (b). Outputs of all fitted models as BMDL and BMDU estimates of E_{Cd}/E_{cr} associated with a 10% increase in the prevalence of CKD (c).

### 4. Discussion

In a dose–response analysis of a large dataset from apparently healthy participants (mean age 48.3 years), older age and higher BMI were independently associated with higher risks of CKD, based on the low eGFR criterion (Table 2). These findings are consistent with the literature reports of age, overweight and obesity as common CKD risk factors [27–30]. In addition to these two risk factors, we have found the measure of long-term exposure to Cd (E_{Cd}/E_{cr}) to be another independent risk factor of CKD (Table 3). An association between low environmental Cd exposure and a decrease in eGFR to levels commensurate with CKD has been observed in population-based studies in the U.S. [31–34], Taiwan [35] and Korea [36–38].

In this study, the risk of CKD was increased by 6.2- and 10.6-fold, when E_{Cd}/E_{cr} ≤ 0.37 µg/g creatinine rose to 0.38–2.49 and ≥ 2.5 µg/g creatinine, respectively. These Cd-dose dependent increases in the risk of CKD were strengthened by the results obtained from the C_{cr}-normalized dataset where the risk of CKD was increased by 4.4- and 20.8-fold, comparing E_{Cd}/C_{cr} ≤ 9.9 ng/L filtrates with E_{Cd}/C_{cr} of 10–49.9 and ≥50 ng/L filtrate, respectively. This confirmation is noteworthy because normalizing E_{Cd} to E_{cr} can cause a wide dispersion of dataset due to the interindividual differences in E_{cr} such as muscle mass which is unrelated to neither Cd exposure nor nephron function [11,12].

Because of such increased variance in datasets introduced by E_{cr}-normalization, the effect of chronic exposure to low-dose Cd on eGFR was not realized. For example, a systematic review and meta-analysis of pooled data from 28 studies reported that the risk of proteinuria was increased by 1.35-fold when comparing the highest vs. lowest category of Cd dose metrics, but an increase in the risk of low eGFR was statistically insignificant (p = 0.10) [39]. An erroneous conclusion that chronic Cd exposure was not associated with a progressive eGFR reduction was also made in another systematic review [40].
A significant relationship was seen between $E_{\text{Cd}}$ and a decrease in eGFR with adjustment for covariates (Table 3). We subsequently applied the BMD method to our $E_{\text{cr}}$ and $C_{\text{cr}}$-normalized datasets to identify $E_{\text{Cd}}/E_{\text{cr}}$ and $E_{\text{Cd}}/C_{\text{cr}}$ values below which an adverse effect of Cd on eGFR can be discerned. The BMDL/BMDU figures of $E_{\text{Cd}}/E_{\text{cr}}$, estimated from the eGFR reduction endpoint were 0.839/1.81, 0.849/1.74 and 0.828/1.71 µg/g creatinine in males, females and all subjects, respectively (Figure 1). The corresponding BMDL/BMDU figures of $E_{\text{Cd}}/C_{\text{cr}}$ were 11.3/24.3, 11.3/24.1 and 10.4/24 ng/L filtrate in males, females and all subjects, respectively (Figure 3).

The BMD values of Cd exposure levels calculated from toxic tubular cell injury and reduced tubular reabsorption of the filtered protein $\beta_2$M can be found in numerous studies [41,42]. In contrast, a report of BMDL/BMDU of Cd exposure levels associated with eGFR reduction could only be found in a study of 790 Swedish women, aged 53–64 years, where the reported BMDL values for the glomerular endpoint were 0.7–1.2 µg/g creatinine [43]. These BMD values were slightly lower than those calculated for females in the present study (0.849/1.74 µg/g creatinine). The differences may be attributable to lower $E_{\text{cr}}$ in Thai women than in Swedish women. Nevertheless, all these BMD values were lower than $E_{\text{Cd}}/E_{\text{cr}}$ of 5.24 µg/g creatinine, which suggested to be a threshold level for the nephrotoxicity of Cd when $E_{\beta_2M}/E_{\text{cr}} > 300$ was used as the POD [8].

In our quantal eGFR endpoint analysis (Figure 2), the BMDL/BMDU values of $E_{\text{Cd}}$ associated with a 10% increase in CKD prevalence were 2.77/5.06 µg/g creatinine (56.1/83.1 ng/L filtrate). These data suggested that population CKD prevalence was likely to be smaller than 10% at $E_{\text{Cd}}/E_{\text{cr}} < 2.77$ µg/g creatinine (<56.1 ng/L filtrates). Thus, the population health risk associated with $E_{\text{Cd}}/E_{\text{cr}} < 2.77$ µg/g creatinine could not be discerned. The impact of Cd exposure on GFR has long been underestimated due to the common practice of normalizing $E_{\text{Cd}}$ to $E_{\text{cr}}$. The comparability of guidelines between populations could be improved by the universal acceptance of a consistent normalization of $E_{\text{Cd}}$ to $C_{\text{cr}}$ that eliminates the effect of muscle mass on $E_{\text{cr}}$, thereby giving a more accurate assessment of the severity of Cd nephropathy [10].

A tolerable intake level of 0.28 µg/kg body weight per day was derived in a risk calculation using pooled data from Chinese population studies [44]. This consumption level, equivalent to 16.8 µg/day for a 60 kg person, was derived from an $E_{\beta_2M}/E_{\text{cr}}$ endpoint where the BMDL value of $E_{\text{Cd}}/E_{\text{cr}}$ for such an endpoint was 3.07 µg/g creatinine. This BMDL estimate was 3.7-fold higher than the BMDL of 0.828 µg/g creatinine derived in the present study. In another Chinese population study, dietary Cd intake estimates at 23.2, 29.6, and 36.9 µg/d were associated with 1.73-, 2.93- and 4.05-fold increments in the prevalence of CKD, compared with the 16.7 µg/d intake level [45]. A diet high in rice, pork, and vegetables was associated with a 4.56-fold increase in the prevalence of CKD [45].

The European Food Safety Authority (EFSA) also used the $\beta_2$M endpoint. However, the EFSA included an uncertainty factor (safety margin), and an intake of 0.36 µg/kg body weight per day for 50 years as an acceptable Cd ingestion level or a reference dose (RfD) [46]. The EFSA designated $E_{\text{Cd}}/E_{\text{cr}}$ of 1 µg/g creatinine as the toxicity threshold level for an adverse effect on kidneys. This Cd excretion of 1 µg/g creatinine is 17 % higher than our NOAEL equivalent of Cd excretion of 0.828 µg/g creatinine.

The Cd toxicity threshold level, RfD and an acceptable consumption level derived from the $\beta_2$M excretion above $\geq 300$ µg/g creatinine do not appear to be without an appreciable health risk. In theory, health-risk assessment should be based on the most sensitive endpoint with consideration given to subpopulations with increased susceptibility to Cd toxicity such as children.

In the present study, the body burden of Cd, measured as $E_{\text{Cd}}/E_{\text{cr}}$, was increased by 3-fold in men and women who smoked cigarettes (Table 1). These results are expected, given that the tobacco plant accumulates high levels of Cd in its leaves, and the volatile metallic Cd and oxide (CdO) generated from cigarette burning are more bioavailable than Cd that enters the body through the gut [47,48].
The diet is the main Cd exposure source for non-smoking and non-occupationally-exposed populations. In a temporal trend analysis of environmental Cd exposure in the U.S., the mean urinary Cd fell by 29% in men (0.58 vs. 0.41 µg/g creatinine, \( p < 0.001 \)) over 18 years (NHANES 1988–2006), but not in women (0.71 vs. 0.63 µg/g creatinine, \( p = 0.66 \)) \[49\]. Such a reduction in Cd exposure among men was attributable to a decrease in smoking prevalence \[50\]. In contrast, total diet studies in Australia \[51\], France \[52\], Spain \[53\] and the Netherlands \[2\] reported that dietary Cd exposure levels among young children exceeded the current health guidance values. These data are concerning for the reasons below.

CKD is a progressive syndrome with high morbidity and mortality and affects 8% to 16% of the world’s population \[27–30\]. An upward trend of its incidence continues, while an adverse effect of Cd on eGFR and the risk of CKD have increasingly been reported. Higher Cd excretion was associated with lower eGFR in studies from Guatemala \[54\] and Myanmar \[55\]. The effect of Cd exposure on eGFR observed in children is particularly concerning. In a prospective cohort study of Bangladeshi preschool children, an inverse relationship between urinary Cd excretion and kidney volume was seen in children at 5 years of age. This was in addition to a decrease in eGFR \[56\]. Urinary Cd levels were inversely associated with eGFR, especially in girls. In another prospective cohort study of Mexican children, the reported mean for Cd intake at the baseline was 4.4 µg/d, which rose to 8.1 µg/d after nine years, when such Cd intake levels showed a marginally inverse association with eGFR \[57\].

5. Conclusions

Environmental exposure to Cd, old age, and elevated BMI are independent risk factors for reduced eGFR. For the first time, the BMDL/BMDU figures of Cd excretion levels associated with a decrease in eGFR have been computed for men and women. The narrow BMDL-BMDU differences indicate the high degree of statistical certainty in these derived NOAEL equivalent figures. The BMDL/BMDU estimates of the Cd excretion associated with a decrease in eGFR in all subjects are 0.828/1.71 µg/g creatinine. The BMDL/BMDU estimates of Cd excretion associated with a 10% increase in the prevalence of CKD are 2.77/5.06 µg/g creatinine. These NOAEL equivalents indicate a decrease in eGFR due to Cd nephropathy occurs at the body burdens lower than those associated with Cd excretion of 5.24 µg/g creatinine and an increase in \( \beta_2 \)M excretion above 300 µg/g creatinine. The established nephrotoxicity threshold level for Cd is outdated and is not protective of human health. Human health risk assessment should be based on current scientific research data.

Author Contributions: Conceptualization, S.S.; methodology, S.S., S.Y. and A.B.-D.; formal analysis, S.S. and A.B.-D.; investigation, S.S. and S.Y.; resources, G.C.G. and D.A.V.; writing—original draft preparation, S.S.; writing—review and editing, G.C.G. and D.A.V.; project administration, S.S. and S.Y. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: This study analyzed archived data taken from published reports \[17,18\]. Ethical review and approval were not applicable.

Informed Consent Statement: All participants took part in the study after giving informed consent.

Data Availability Statement: All data are contained within this article.

Acknowledgments: This work was supported with resources from the Kidney Disease Research Collaborative, Translational Research Institute and the Department of Nephrology, Princess Alexandra Hospital. It was also supported by the resources of the Department of Toxicology “Akademik Danilo Soldatović”, University of Belgrade-Faculty of Pharmacy, Serbia.

Conflicts of Interest: The authors have declared no potential conflict of interest.
References

1. Satarug, S.; Vesey, D.A.; Gobe, G.C. Current health risk assessment practice for dietary cadmium: Data from different countries. Food Chem. Toxicol. 2017, 106, 430–445. [CrossRef] [PubMed]

2. Boon, P.E.; Pustjens, A.M.; Te Biesebeek, J.D.; Brust, G.M.H.; Castenmiller, J.J.M. Dietary intake and risk assessment of elements for 1- and 2-year-old children in the Netherlands. Food Chem. Toxicol. 2022, 161, 112810. [CrossRef] [PubMed]

3. Fechner, C.; Hackethal, C.; Höpfner, T.; Dietrich, J.; Bloch, D.; Lindtner, O.; Sarvan, I. Results of the BfR MEAL Study: In Germany, mercury is mostly contained in fish and seafood while cadmium, lead, and nickel are present in a broad spectrum of foods. Food Chem. X 2022, 14, 100326. [CrossRef] [PubMed]

4. Aoshima, K. Epidemiology of renal tubular dysfunction in the inhabitants of a cadmium-polluted area in the Jinzu River basin in Toyama Prefecture. Tohoku J. Exp. Med. 1987, 152, 151–172. [CrossRef]

5. Horiguchi, H.; Aoshima, K.; Oguma, E.; Sasaki, S.; Miyamoto, K.; Hosoi, Y.; Katoh, T.; Kayama, F. Latest status of cadmium accumulation and its effects on kidneys, bone, and erythropoiesis in inhabitants of the formerly cadmium-polluted Jinzu River Basin in Toyama, Japan, after restoration of rice paddies. Int. Arch. Occup. Environ. Health 2010, 83, 953–970. [CrossRef] [PubMed]

6. Kurata, Y.; Katsuta, O.; Doi, T.; Kawasuso, T.; Hiratsuka, H.; Tsuchitani, M.; Umemura, T. Chronic cadmium treatment induces tubular nephropathy and osteomalacic osteopenia in ovariectomized cynomolgus monkeys. Vet. Pathol. 2014, 51, 919–931. [CrossRef] [PubMed]

7. Wong, C.; Roberts, S.M.; Saab, I.N. Review of regulatory reference values and background levels for heavy metals in the human diet. Regul. Toxicol. Pharmacol. 2022, 130, 105122. [CrossRef] [PubMed]

8.  

9. Satarug, S.; Vesey, D.A.; Nishijo, M.; Ruangyuttikarn, W.; Gobe, G.C. The inverse association of glomerular function and urinary β2-MG excretion and its implications for cadmium health risk assessment. Environ. Res. 2019, 173, 40–47. [CrossRef]

10. Satarug, S.; Vesey, D.A.; Gobe, G.C. Dose-response analysis of the tubular and glomerular effects of chronic exposure to environmental cadmium. Int. J. Environ. Res. Public Health 2022, 19, 10572. [CrossRef]

11. Satarug, S.; Vesey, D.A.; Ruangyuttikarn, W.; Nishijo, M.; Gobe, G.C.; Phelps, K.R. The source and pathophysiologic significance of excreted cadmium. Toxics 2019, 7, 55. [CrossRef]

12. Satarug, S.; Vesey, D.A.; Nishijo, M.; Ruangyuttikarn, W.; Gobe, G.C.; Phelps, K.R. The effect of cadmium on GFR is clarified by normalization of excretion rates to creatinine clearance. Int. J. Mol. Sci. 2021, 22, 1762. [CrossRef]

13. Schnaper, H.W. The tubulointerstitial pathophysiology of progressive kidney disease. Adv. Chronic Kidney Dis. 2017, 24, 107–116. [CrossRef]

14. Sand, S.; Victorin, K.; Filipsson, A.F. The current state of knowledge on the use of the benchmark dose concept in risk assessment. J. Appl. Toxicol. 2008, 28, 405–421. [CrossRef] [PubMed]

15. EFSA Scientific Committee. Update: Use of the benchmark dose approach in risk assessment. EFSA J. 2017, 15, 4658.

16. Moffett, D.B.; Mumtaz, M.M.; Sullivan, D.W., Jr.; Whittaker, M.H. Chapter 13, General Considerations of Dose-Effect and Dose-Response Relationships. In Handbook on the Toxicology of Metals, 5th ed.; Volume I: General Considerations; Nordberg, G., Costa, M., Eds.; Academic Press: Cambridge, MA, USA, 2022; pp. 299–317.

17. Satarug, S.; Swaddiwudhipong, W.; Ruangyuttikarn, W.; Nishijo, M.; Ruiz, P. Modeling cadmium exposures in low- and high-exposure areas in Thailand. Environ. Health Perspect. 2013, 121, 531–536. [CrossRef] [PubMed]

18. Yimthiang, S.; Poudyung, P.; Khamphaya, T.; Kuraeid, S.; Wongsrith, P.; Vesey, D.A.; Gobe, G.C.; Satarug, S. Effects of environmental exposure to cadmium and lead on the risks of diabetes and kidney dysfunction. Int. J. Environ. Res. Public Health 2022, 19, 2259. [CrossRef] [PubMed]

19. Denic, A.; Elsheribiny, H.; Rule, A.D. In-vivo techniques for determining nephron number. Curr. Opin. Nephrol. Hypertens. 2019, 28, 545–551. [CrossRef] [PubMed]

20. Levey, A.S.; Becker, C.; Inker, L.A. Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: A systematic review. JAMA 2015, 313, 837–846. [CrossRef]

21. Soveri, I.; Berg, U.B.; Björk, J.; Eliander, C.G.; Grubb, A.; Meijare, I.; Sterner, G.; Bäck, S.E.; SBU GFR Review Group. Measuring GFR: A systematic review. Am. J. Kidney Dis. 2014, 64, 411–424. [CrossRef]

22. White, C.A.; Allen, C.M.; Akbari, A.; Collier, C.P.; Holland, D.C.; Day, A.G.; Knoll, G.A. Comparison of the new and traditional CKD-EPI GFR estimation equations with urinary inulin clearance: A study of equation performance. Clin. Chim. Acta 2019, 488, 189–195. [CrossRef]

23. Phelps, K.R.; Gosmanova, E.O. A generic method for analysis of plasma concentrations. Clin. Nephrol. 2020, 94, 43–49. [CrossRef] [PubMed]

24. Slob, W.; Moerbeek, M.; Raunioamaa, E.; Piersma, A.H. A statistical evaluation of toxicity study designs for the estimation of the benchmark dose in continuous endpoints. Toxicol. Sci. 2005, 84, 167–185. [CrossRef] [PubMed]

25. Slob, W.; Setzer, R.W. 2014. Shape and steepness of toxicological dose-response relationships of continuous endpoints. Crit. Rev. Toxicol. 2014, 44, 270–297. [CrossRef] [PubMed]
26. Zhu, Y.; Wang, T.; Jelsovsky, I.J. Bootstrap estimation of benchmark doses and confidence limits with clustered quantal data. Risk Anal. 2007, 27, 447–465. [CrossRef] [PubMed]

27. Nichols, G.A.; Dérusz-Luty, A.; Brodovicz, K.G.; Kimes, T.M.; Rosales, A.G.; Hauske, S.J. Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes. BMC Nephrol. 2020, 21, 167.

28. George, C.; Moguero, A.; Okpechi, I.; Echouffo-Tcheugui, J.B.; Kenne, A.P. Chronic kidney disease in low-income to middle-income countries: Case Increased Screening. BMJ Glob Health. 2017, 2, e000256. [CrossRef]

29. George, C.; Echouffo-Tcheugui, J.B.; Jaar, B.G.; Okpechi, I.G.; Kenne, A.P. The need for screening, early diagnosis, and prediction of chronic kidney disease in people with diabetes in low- and middle-income countries-a review of the current literature. BMC Med. 2022, 20, 247. [CrossRef] [PubMed]

30. Kalantar-Zadeh, K.; Jafar, T.H.; Nitsch, D.; Neuen, B.L.; Perkovic, V. Chronic kidney disease. Lancet 2021, 398, 786–802. [CrossRef]

31. Ferraro, P.M.; Costanzi, S.; Naticchia, A.; Sturmiolo, A.; Gambaro, G. Low level exposure to cadmium increases the risk of chronic kidney disease: Analysis of the NHANES 1999–2006. BMC Public Health 2010, 10, 304. [CrossRef] [PubMed]

32. Navas-Acien, A.; Tellez-Plaza, M.; Guallar, E.; Muntner, P.; Silbergeld, E.; Jaar, B.; Weaver, V. Blood cadmium and lead and chronic kidney disease in US adults: A joint analysis. Ann. J. Epidemiol. 2009, 170, 1156–1164. [CrossRef]

33. Lin, Y.S.; Ho, W.C.; Cafrey, J.L.; Sonawane, B. Low serum zinc is associated with elevated risk of cadmium nephrotoxicity. Environ. Res. 2014, 134, 33–38. [CrossRef] [PubMed]

34. Madrigal, J.M.; Ricardo, A.C.; Persky, V.; Turyk, M. Associations between blood cadmium concentration and kidney function in the U.S. population: Impact of sex, diabetes and hypertension. Environ. Res. 2018, 169, 180–188. [CrossRef] [PubMed]

35. Tsai, K.F.; Hsu, P.C.; Lee, C.T.; Kung, C.T.; Chang, Y.C.; Fu, L.M.; Ou, Y.C.; Lan, K.C.; Yen, T.H.; Lee, W.C. Association between enzyme-linked immunosorbent assay-measured kidney injury markers and urinary cadmium levels in chronic kidney disease. J. Clin. Med. 2021, 11, 156. [CrossRef] [PubMed]

36. Myong, J.-P.; Kim, H.-R.; Baker, D.; Choi, B. Blood cadmium and moderate-to-severe glomerular dysfunction in Korean adults: Analysis of KNHANES 2005–2008 data. Int. Arch. Occup. Environ. Health 2012, 85, 885–893. [CrossRef]

37. Chung, S.; Chung, J.H.; Kim, S.J.; Koh, E.S.; Yoon, H.E.; Park, C.W.; Chang, Y.S.; Shin, S.J. Blood lead and cadmium levels and renal function in Korean adults. Clin. Exp. Nephrol. 2014, 18, 726–734. [CrossRef]

38. Park, Y.; Lee, S.J. Association of blood heavy metal levels and renal function in Korean adults. Int. J. Environ. Res. Public Health 2022, 19, 6646. [CrossRef]

39. Jalili, C.; Kazemi, M.; Cheng, H.; Mohammadi, H.; Babaei, A.; Taheri, E.; Moradi, S. Associations between exposure to heavy metals and the risk of chronic kidney disease: A systematic review and meta-analysis. Crit. Rev. Toxicol. 2021, 51, 165–182. [CrossRef]

40. Byber, K.; Lison, D.; Veroustraete, V.; Dressel, H.; Hotz, P. Cadmium or cadmium compounds and chronic kidney disease in workers and the general population: A systematic review. Crit. Rev. Toxicol. 2016, 46, 191–240. [CrossRef]

41. Liu, C.; Li, Y.; Zhu, C.; Dong, Z.; Zhang, K.; Zhao, Y.; Xu, Y. Benchmark dose for cadmium exposure and elevated N-acetyl-β-D-glucosaminidase: A meta-analysis. Environ. Sci. Pollut. Res. Int. 2016, 23, 20528–20538. [CrossRef]

42. Pócsi, I.; Dockrell, M.E.; Price, R.G. Nephrotoxic biomarkers with specific indications for metallic pollutants: Implications for environmental health. Biomark. Insights 2022, 17, 11772719221111882. [CrossRef]

43. Suwazono, Y.; Sand, S.; Vahter, M.; Filipsson, A.F.; Skerfving, S.; Lidfeldt, J.; Akesson, A. Benchmark dose for cadmium-induced renal effects in humans. Environ. Health Perspect. 2006, 114, 1072–1076. [CrossRef] [PubMed]

44. Qing, Y.; Yang, J.; Zhu, Y.; Li, Y.; Zheng, W.; Wu, M.; He, G. Dose-response evaluation of urinary cadmium and kidney injury biomarkers in Chinese residents and dietary limit standards. Environ. Health 2021, 20, 75. [CrossRef] [PubMed]

45. Shi, Z.; Taylor, A.W.; Riley, M.; Byles, J.; Liu, J.; Noakes, M. Association between dietary patterns, cadmium intake and chronic kidney disease among adults. Clin. Nutr. 2018, 37, 276–284. [CrossRef] [PubMed]

46. EFSAs. European Food Safety Authority, Statement on tolerable weekly intake for cadmium. EFSA J. 2011, 9, 7975.

47. Repić, A.; Bulat, P.; Antonijević, B.; Antunović, M.; Džudović, J.; Buha, A.; Bulat, Z. The influence of smoking habits on cadmium and lead blood levels in the Serbian adult people. Environ. Sci. Pollut. Res. Int. 2020, 27, 751–760. [CrossRef]

48. Pappas, R.S.; Fresquez, M.R.; Watson, C.H. Cigarette smoke cadmium breakthrough from traditional filters: Implications for exposure. J. Anal. Toxicol. 2015, 39, 45–51. [CrossRef]

49. Ferraro, P.M.; Sturmiolo, A.; Naticchia, A.; D’Alonzo, S.; Gambaro, G. Temporal trend of cadmium exposure in the United States population suggests gender specificities. Intern. Med. J. 2012, 42, 691–697. [CrossRef]

50. Tellez-Plaza, M.; Navas-Acien, A.; Caldwell, K.L.; Menke, A.; Muntner, P.; Guallar, E. Reduction in cadmium exposure in the United States population, 1988–2008: The contribution of declining smoking rates. Environ. Health Perspect. 2012, 120, 204–209. [CrossRef]

51. Callan, A.; Hinwood, A.; Devine, A. Metals in commonly eaten groceries in Western Australia: A market basket survey and dietary assessment. Food Addit. Contam. A 2014, 31, 1968–1981. [CrossRef]

52. Arnich, N.; Sirot, V.; Riviere, G.; Jean, J.; Noel, L.; Guerin, T.; Leblanc, J.-C. Dietary exposure to trace elements and health risk assessment in the 2nd French Total Diet Study. Food Chem. Toxicol. 2012, 50, 2432–2449. [CrossRef]
53. González, N.; Calderón, J.; Rúbies, A.; Timoner, I.; Castell, V.; Domingo, J.L.; Nadal, M. Dietary intake of arsenic, cadmium, mercury and lead by the population of Catalonia, Spain: Analysis of the temporal trend. *Food Chem. Toxicol.* **2019**, *132*, 110721. [CrossRef] [PubMed]

54. Butler-Dawson, J.; James, K.A.; Krisher, L.; Jaramillo, D.; Dally, M.; Neumann, N.; Pilloni, D.; Cruz, A.; Asensio, C.; Johnson, R.J.; et al. Environmental metal exposures and kidney function of Guatemalan sugarcane workers. *J. Expo. Sci. Environ. Epidemiol.* **2022**, *32*, 461–471. [CrossRef] [PubMed]

55. Win-Thu, M.; Myint-Thein, O.; Win-Shwe, T.-T.; Mar, O. Environmental cadmium exposure induces kidney tubular and glomerular dysfunction in the Myanmar adults. *J. Toxicol. Sci.* **2021**, *46*, 319–328. [CrossRef] [PubMed]

56. Skröder, H.; Hawkesworth, S.; Kippler, M.; El Arifeen, S.; Wagatsuma, Y.; Moore, S.E.; Vahter, M. Kidney function and blood pressure in preschool-aged children exposed to cadmium and arsenic-potential alleviation by selenium. *Environ. Res.* **2015**, *140*, 205–213. [CrossRef] [PubMed]

57. Rodríguez-López, E.; Tamayo-Ortiz, M.; Ariza, A.C.; Ortiz-Panozo, E.; Deierlein, A.L.; Pantic, I.; Tolentino, M.C.; Estrada-Gutiérrez, G.; Parra-Hernández, S.; Espejel-Núñez, A.; et al. Early-life dietary cadmium exposure and kidney function in 9-year-old children from the PROGRESS cohort. *Toxics* **2020**, *8*, 83. [CrossRef]